Recordati
Via Matteo Civitali, 1, Milan, Lombardia, 20148, Italy
Overview
Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of over 3,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey and in the United States of America. A field force of more than 1,700 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2012 was € 828.3 million, operating income was € 167.0 million and net income was € 118.5 million.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 1
- Active investors
- 7
Sector focus
- Biotechnology
- Health Care
- Manufacturing
Investment portfolio
- STRM.BIO
Led · Seed · Jan 2026
STRM.BIO is a Cambridge, Massachusetts–based biotechnology company focused on a non-viral, cell-derived delivery modality for in vivo gene and cell therapies. Its megakaryocyte-derived vesicle (MV) platform is designed to safely and precisely carry complex genetic cargos directly to bone marrow, overcoming the immunogenicity and payload limits of viral and synthetic vectors. The company’s initial pipeline targets Fanconi anemia and other rare hematological disorders, while longer-term plans include in vivo CAR-T and broader immune-cell engineering applications. Recent funding activity has provided meaningful runway: $8 million in Series Seed 2 equity coupled with an $8.4 million ARPA-H contract brought total seed-stage capital raised in late 2025 to $16.4 million. STRM.BIO intends to use the proceeds to complete platform validation, advance preclinical programs toward the clinic, and prepare for a forthcoming Series A. Backers now include strategic pharma investors Recordati and Boehringer Ingelheim Venture Fund alongside Delos Capital and Blue Bay Capital. No revenue or clinical data have been disclosed to date.